ADC

198개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved198 programs
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan combined with envafolimab)

Advanced Biliary Tract Cancers · Advanced Biliary Tract Cancers

#AdvancedBiliaryTractCancers#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
ADCLimited DatastaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
ADCLimited DatastaleTG Therapeutics, Inc.Phase 1

brentuximab vedotin (Adcetris, TGR-1202 + brentuximab vedotin)

Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Phase1#antibody-drug-conjugate#TG
Trials 1Status Active
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

SHR-A1811 (Trastuzumab Rezetecan, Trastuzumab Rezetecan (SHR-A1811))

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveBreastCancer+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting
ADCLimited DatastaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
ADCLimited DatastaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
ADCLimited DatastaleMabwell (Shanghai) Bioscience C…Phase 1

bulumtatug fuvedotin (bulumtatug fuvedotin)

Triple Negative Breast Cancer · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#antibody-drug-conjugate#Mabwell
Trials 1Status Recruiting
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active
ADCLimited DatastaleDaiichi SankyoPhase 2

T-DXd (fam-trastuzumab deruxtecan-nxki, fam-trastuzumab deruxtecan-nxki (T-DXd))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and CDX-301 (glembatumumab vedotin and CDX-301)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and varlilumab (glembatumumab vedotin and varlilumab)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, pertuzumab, called T-DXd+P)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting

10 / 10 pages

← PreviousNext →